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Abstract
Identification of potential drug–associated indications is critical for either approved or novel
drugs in drug repositioning. Current computational methods based on drug similarity and
disease similarity have been developed to predict drug–disease associations. When more
reliable drug- or disease-related information becomes available and is integrated, the prediction precision can be continuously improved. However, it is a challenging problem to
effectively incorporate multiple types of prior information, representing different characteristics of drugs and diseases, to identify promising drug–disease associations. In this study,
we propose an overlap matrix completion (OMC) for bilayer networks (OMC2) and tri-layer
networks (OMC3) to predict potential drug-associated indications, respectively. OMC is
able to efficiently exploit the underlying low-rank structures of the drug–disease association
matrices. In OMC2, first of all, we construct one bilayer network from drug-side aspect and
one from disease-side aspect, and then obtain their corresponding block adjacency matrices. We then propose the OMC2 algorithm to fill out the values of the missing entries in
these two adjacency matrices, and predict the scores of unknown drug–disease pairs.
Moreover, we further extend OMC2 to OMC3 to handle tri-layer networks. Computational
experiments on various datasets indicate that our OMC methods can effectively predict the
potential drug–disease associations. Compared with the other state-of-the-art approaches,
our methods yield higher prediction accuracy in 10-fold cross-validation and de novo experiments. In addition, case studies also confirm the effectiveness of our methods in identifying
promising indications for existing drugs in practical applications.

Author summary
This work introduces a computational approach, namely overlap matrix completion
(OMC), to predict potential associations between drugs and diseases. The novelty of
OMC lies in constructing an efficient framework of incorporating multiple types of prior
information in bilayer and tri-layer networks. OMC for bilayer networks (OMC2) can
approximate the low-rank structures of the drug–disease association matrices from both
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drug-side and disease-side. In addition, we further improve the prediction accuracy by
extending OMC to handle tri-layer networks and develop its corresponding algorithm
(OMC3). To evaluate the performance of OMC2 and OMC3, we conduct 10-fold crossvalidation and de novo experiments on three datasets. Our computational results demonstrate that both OMC2 and OMC3 generally outperform five state-of-the-art methods in
terms of ROC curve, PR curve, and top-ranked predictions.

Introduction
The development of new drugs is extremely time-consuming and expensive [1]. It is reported
that the average time of developing a new drug is more than 13.5 years and the cost exceeds $1.8
billion dollars [2], while only a relatively small number of novel drugs are approved by US Food
and Drug Administration (FDA) each year. Identifying new uses of existing drugs, known as
drug repositioning, has been popularly used for the pharmaceutical industry and research community. Since the existing drugs have already owned safety, efficacy, and toleration data after
numerous experiments and clinical trials, identifying new and reliable indications for commercialized drugs can sharply reduce time and costs. In addition, some successfully repositioned
drugs, such as raloxifene, sildenafil, and thalidomide, have produced great revenues for their
patent companies. Hence, drug repositioning is an important strategy of drug discovery in
pharmaceutical industry.
The computational methods for drug repositioning have received much attention recently,
as the traditional manual experimental investigation is complicated and inefficient. In recent
years, many types of computational approaches have been proposed, including semantic inference, network-based analysis, and machine learning. The network-based methods are one of
the popularly-used approaches to identify potential drug–disease associations. Based on the
guilt-by-association principle, Wang et al. constructed a heterogenous graph between drug
and target and proposed the HGBI (Heterogeneous Graph Based Inference) algorithm to predict potential drug–target interactions [3]. The HGBI algorithm is also used for prediction of
drug–disease associations [4]. Based on the propagation flow algorithm, Martinez et al. proposed a network-based prioritization method named DrugNet for drug repositioning [5]. The
DrugNet algorithm can perform both disease–drug and drug–disease prioritization by integrating drug, disease, and target information. In [6], the MBiRW method addressed the drugrepositioning problem by applying a bi-random walk algorithm on heterogeneous network
with comprehensive similarity measures for drugs and diseases, obtained by utilizing logistic
function [7] and ClusterONE [8].
Machine learning methods have attracted a lot of attention in recent years. Based on the
common assumption that similar drugs tend to connect with similar diseases, Gottlieb et al.
calculated five drug–drug similarity measures and two disease–disease similarity measures for
drug-associated indication prediction, and presented a method (PREDICT) to identify potential drug indications for approved drugs [9]. Integrating chemical structure, drug–target interaction, and side-effect data, Wang et al. presented an approach called PreDR for drug–disease
association prediction [10]. PreDR treated the prediction problem as a binary classification
problem by defining a kernel function and applying an SVM-based learning algorithm. In
[11], a matrix factorization model was developed to predict new indications for known drugs
by incorporating the interaction network of genes. Luo et al. proposed a drug repositioning
recommendation system (DRRS) [12]. Specifically, a heterogeneous network was constructed
by integrating drug similarities, disease similarities, and drug–disease associations and the
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adjacency matrix of the large-scale heterogeneous network was considered as a low-rank
matrix. The singular value thresholding algorithm (SVT) [13] was implemented to complete
the missing entries of a drug–disease association matrix. Yang et al. further proposed a
bounded nuclear norm regularization (BNNR) model [14], not only tolerating the noisy similarities of drugs and diseases by employing regularization, but also ensuring that all predicted
values are within the interval of [0, 1]. However, the computational cost of both DRRS and
BNNR increases sharply when target (protein/gene) information is incorporated into the heterogeneous drug–disease network.
In this study, we propose an overlap matrix completion for bilayer networks (OMC2) and
tri-layer networks (OMC3) to predict potential indications for approved and new drugs. We
design two different networks from drug-side aspect and disease-side aspect, instead of constructing a large-scale heterogeneous drug–disease network. This can significantly reduce the
computational complexity for matrix completion. Meanwhile, a BNNR model [14] developed
in our previous work is implemented to fill out the missing entries in the block adjacency
matrix of these networks. We evaluate the performance of OMC2 and OMC3 in three different
datasets and compare them with five latest approaches for drug repositioning. Our computational results show that our methods yield better accuracy in predicting potential drug–disease
associations.

Materials and methods
In this section, we introduce OMC for bilayer networks (OMC2) and tri-layer networks
(OMC3) to identify potential indications for both known and novel drugs. First of all, a concise description of experimental datasets is presented. In bilayer heterogeneous networks, we
integrate drug–drug, disease–disease, and drug–disease information. In tri-layer heterogeneous networks, besides the above three kinds of data, drug–protein and disease–protein
associations are considered. Then, we present the OMC2 algorithm for drug–disease bilayer
networks to predict novel drug–disease associations. Finally, we extend OMC2 to an OMC3
algorithm in handling the tri-layer networks, where the target-related information is also
incorporated.

Datasets
To construct bilayer and tri-layer networks, we collected drug, disease, and target protein
information from published literatures and related authoritative databases. The approaches to
collect association information and to compute similarity are described below.
Drug–disease associations. Confirmed drug–disease associations were obtained from the
supplementary material of [9], which was admittedly treated as the gold standard dataset.
There were 1, 933 associations between 593 drugs registered from DrugBank [15] and 313 diseases listed in the Online Mendelian Inheritance in Man (OMIM) database [16].
Drug–drug similarity. Drug–drug similarities were calculated based on chemical structures.
The Canonical Simplified Molecular Input Line-Entry System (SMILES) [17] of these 593
drugs were downloaded from DrugBank. Then, the Chemical Development Kit (CDK) [18]
was utilized to compute hashed fingerprints for each drug with default parameters. Finally, the
similarity between two drugs was measured by the Tanimoto score [19] in the range of [0, 1].
Disease–disease similarity. Disease–disease similarities were computed by MimMiner [20],
which identifies similarity of appearance of MESH (medical subject headings vocabulary)
terms between two diseases in medical descriptions from the OMIM database. In the MimMiner program, the disease–disease similarity was normalized to the interval of [0, 1].
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Drug–protein interactions. The interactions between drugs and proteins were collected
from DrugBank. We collected 3, 184 drug–target (protein) interactions between 576 relevant
drugs of the gold standard dataset and 975 proteins.
Disease–protein associations. We collected disease–protein associations in two steps. In the
first step, we downloaded the interactions between diseases included in the gold standard dataset and genes from CTD [21], and the total of 475 disease–gene interactions were collected.
Secondly, these genes were mapped into 849 proteins in UniprotKB database [22]. There were
1, 066 associations between 166 diseases and 849 proteins at last.

OMC algorithm for bilayer networks
Two drug–disease bilayer networks and corresponding adjacency matrices. We construct two heterogeneous drug–disease bilayer networks. One is composed of a drug–drug network and a drug–disease network and the other is of a disease–disease network and a drug–
disease network. Fig 1 shows the workflow for constructing two bilayer networks and their
corresponding block adjacency matrices.
For the drug–drug network with m drug nodes, let ARR 2 IRm�m be its adjacency matrix,
where element (ARR)ij represents the similarity between drugs ri and rj. Similarly, ADD 2 IRn�n
is the adjacency matrix of the disease–disease network with n disease nodes, where (ADD)ij

Fig 1. The workflow of constructing the DrNet-Dis network and the DisNet-Dr network. (a) Drug–drug network and its similarity
matrix. (b) Drug–disease associations and KNN preprocessing. (c) Disease–disease network and its similarity matrix. (d) DrNet-Dis
network and its block adjacency matrix. (e) DisNet-Dr network and its block adjacency matrix.
https://doi.org/10.1371/journal.pcbi.1007541.g001
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denotes the similarity between diseases di and dj. For the drug–disease network, let ADR 2
IRn�m be its adjacency matrix (drug–disease association matrix), where (ADR)ij is set to 1 if
there exists an experimentally validated association between di and rj, otherwise 0.
DrNet-Dis network. The DrNet-Dis network, illustrated in Fig 1(a), 1(b) and 1(d), is constructed by integrating the drug–drug network and the drug–disease network. For the sake of
generality in applications, we take some novel disease nodes into account, which are not associated with any known drug node. For instance, d4 is a new disease node in Fig 1(b), and the
corresponding row of ADR is a zero vector, which causes difficulty in matrix completion
and affects the performance of prediction. To address this cold-start problem, we conduct a
K-Nearest Neighbor (KNN) preprocessing step for these new diseases. Specifically, for each
novel disease dp, K nearest neighbor diseases of dp are picked based on their disease similarities
in descending order. We update the corresponding row vector of disease dp in the drug–disease association matrix by filling out a part of weighted association information. The detail of
the KNN preprocessing algorithm is described by Algorithm 1. After the KNN preprocessing
step, an updated drug–disease association matrix ADR1 is obtained and the block adjacency
matrix M1 2 IRðmþnÞ�m of the DrNet-Dis network is presented as follows,
"
M1 ¼

ARR

#
:

ADR1
DisNet-Dr network. The DisNet-Dr network, demonstrated by Fig 1(b), 1(c) and 1(e), is
constructed by integrating the disease–disease network and the drug–disease network. For
some novel drugs (e.g., drug r2 in Fig 1(b)), the corresponding columns of ADR are zero vectors. Similarly, the KNN preprocessing step is also implemented for these new drugs by Algorithm 1, and a new corresponding association matrix ADR2 is developed. Finally, the block
adjacency matrix M2 2 IRn�ðmþnÞ of the DisNet-Dr network is denoted as follows,
M2 ¼ ½ ADR2

ADD �:

Actually, the above KNN preprocessing step is not required if there is no novel disease or
drug node. M1 and M2 are the to-be-complete matrices.
Algorithm 1: KNN Preprocessing Algorithm
Input: The drug similarity matrix ARR 2 IRm�m , the disease similarity
matrix ADD 2 IRn�n , the disease–drug association matrix ADR 2 IRn�m may contain some zero rows or columns, and the neighborhood size K.
Output: Updated ADR1 and ADR2.
1. Initialize ADR1 = ADR and ADR2 = ADR;
2. Find index numbers of all zero rows of the matrix ADR1, which are
denoted as {i1, i2, . . ., is} � {1, 2, . . ., m}. D0 ¼ fdi1 ; di2 ; . . . ; dis g represents
the corresponding disease set. /� Entries of D0 actually are novel diseases, where di1 represents i1-th disease in all diseases.� /
for each disease dp 2 D0 do
3. U ¼ KNNðADD ; K; dp Þ; /� KNN is a function for finding the K nearest
neighbors of disease node dp based on similarity matrix ADD in descend�
ing order.
P /
4. Sd ¼
ADD ðdp ; du Þ;
du 2U

5. ADR1 ðp; :Þ ¼

P
du 2U

ADD ðdp ;du Þ
Sd

� ADR ðdu ; :Þ;

�

/ ADR1(p, :) notes the p-th row of matrix ADR1 and the denominator is
the normalization term.� /
end for
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6. Find index numbers of all zero columns of the matrix ADR2, which are
denoted as {j1, j2, . . ., jt} � {1, 2, . . ., n}. R0 ¼ frj1 ; rj2 ; . . . ; rjt g represents
the corresponding drug set. /� Entries of R0 actually are novel drugs,
where rj1 represents the j1-th drug in all drugs.� /
for each drug rq 2 R0 do
7. V ¼ KNNðARR ; K; rq Þ; /� KNN is a function for finding the K nearest
neighbors of drug node rq based on similarity matrix ARR in descending
order.�P
/
8. Sr ¼
ADD ðrq ; rv Þ;
rv 2V

9. ADR2 ð:; qÞ ¼

P
rv 2V

ARR ðrq ;rv Þ
Sr

� ADR ð:; rv Þ;

/� ADR2(:, q) notes the q-th column of matrix ADR2 and the denominator is
the normalization term.� /
end for
10. return ADR1 and ADR2.

BNNR model. Matrix completion, whose goal is to recover the missing elements of matrix
from only a few observations, has been widely used in many applications. Under the low-rank
assumption, matrix completion is generally formulated as the following nuclear norm minimization problem
min kXk�
X

ð1Þ

s:t: P O ðXÞ ¼ P O ðMÞ:
where kXk� denotes the nuclear norm of X, which is defined as the sum of all singular values
of X. M is the incomplete matrix, O is a set including index pairs (i, j) of all known elements in
M, and P O is the projection operator projecting matrix X onto O, which is defined as
(
ðP O ðXÞÞij ¼

Xij ;
0:

ði; jÞ 2 O
ði; jÞ 2
=O

In the drug–disease association matrix, the entry value 1 denotes an experimentally validated
indication while 0 indicates the association has not been validated yet. As a result, the predicted drug–disease association values are expected to fall in the interval of [0, 1], indicating
the likelihood of being a true association. Therefore, a predicted value beyond the [0, 1] range
is meaningless in the context of the application. To enforce the predicted values within the
interval of [0, 1], a bounded constraint is added into the matrix completion model. In addition,
due to the large amount of “noise” when calculating drug similarity and disease similarity, we
relax the constraint satisfaction condition by incorporating a regularization term. As a result,
we have proposed the bounded nuclear norm regularization (BNNR) described in [14] as follows,
a
min kXk� þ kP O ðXÞ
X
2

2

P O ðMÞkF

ð2Þ

s:t: 0 � X � 1:
where α > 0 is a harmonic parameter to balance the nuclear norm and the error term and 0 �
X � 1 represents 0 � Xij � 1 for all i, j. A simple and effective algorithm is designed to solve
model (2) by using the alternating direction method of multipliers (ADMM). By introducing a
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new splitting matrix W, (2) can be formulated as the following equivalent form,
a
min kXk� þ kP O ðWÞ
X
2

2

P O ðMÞkF
ð3Þ

s:t: X ¼ W;
0 � W � 1:
The augmented Lagrangian function of model (3) is
a
LðW; X; Y; a; bÞ ¼ kXk� þ kP O ðWÞ
2
þTrðY T ðX

2

P O ðMÞkF

b
WÞÞ þ kX
2

ð4Þ
2

WkF ;

where Y is the Lagrange multiplier and β > 0 is the penalty parameter. By applying ADMM,
we can obtain the following iterative scheme:
Wkþ1 ¼ arg min LðW; Xk ; Yk ; a; bÞ;

ð5Þ

0�W�1

Xkþ1 ¼ arg min LðWkþ1 ; X; Yk ; a; bÞ;

ð6Þ

X

Ykþ1 ¼ Yk þ bðXkþ1

Wkþ1 Þ:

ð7Þ

We use the inverse operator [23] to solve Eq (5) and acquire a closed-form solution W� as
follows,
W � ¼ ðI

a
1
a
P O Þð Yk þ P O ðMÞ þ Xk Þ;
aþb
b
b

where I denotes the identity operator. Moreover, to limit the element values of Wk+1 in the
interval of [0, 1], we utilize the following projection operator
Wkþ1 ¼ Q½0;1� ðW � Þ;

ð8Þ

where Q½0;1� is defined as
8
1;
>
>
>
<
ðQ½0;1� ðW � ÞÞij ¼ Wij� ;
>
>
>
:
0:

Wij� > 1
0 � Wij� � 1
Wij� < 0

By rearranging the terms of (6), we have
Xkþ1

�
b�
¼ arg min kXk� þ �
X
2�
X
¼ D1 ðWkþ1
b

ðWkþ1

�2
�
1
Y Þ�
b k �F

ð9Þ

1
Y Þ;
b k

where Dt ðXÞ is the singular value shrinkage (SVT) operator [13] [24]. Specifically, SVT
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operator is defined as
Dt ðXÞ ¼

si �t
X
ðsi

tÞui vTi ;

i¼1

where σi is the ith singular value of X larger than threshold τ, while ui and vi are the left and
right singular vectors corresponding to σi, respectively.
Algorithm 2 presents an iterative BNNR scheme for solving the model (2). After performing
BNNR algorithm, we can obtain a completed matrix M� , where all the unknown entries of
matrix M have been filled out.
Algorithm 2: BNNR Algorithm
Input: The to-be-complete M, parameters α, and β.
Output: Completed matrix M� .
1. initialize X1 = PΩ(M), W1 = X1, Y1 = X1;
2. k
1;
repeat
3. Wkþ1
Q½0;1� ðW � Þ;
�
�
4. Xkþ1
D1 Wkþ1 b1 Yk ;
b

5. Yk+1
Yk + β(Xk+1 − Wk+1);
6. k
k + 1;
until convergence
7. M� = Wk;
8. return M� .

OMC2 algorithm. We propose the OMC algorithm for bilayer networks (OMC2) to predict the potential drug–disease associations, whose goal is to obtain the low-rank matrices of
drug–disease relationships from drug-side information and disease-side information. Firstly,
we combine the updated disease–drug association matrix with the drug similarity matrix and
create a block adjacency matrix M1, as illustrated in Fig 1(d). Meanwhile, from the diseaseside, we combine the updated disease–drug association matrix with the disease similarity
matrix and generate a block adjacency matrix M2, as illustrated in Fig 1(e). Secondly, the
BNNR algorithm is implemented to fill out the unknown entries of M1 and M2. Finally, we calculate the average of two predicted drug–disease association matrices to obtain the final predicted matrix A�DR . Each element ðA�DR Þij represents the predicted score between disease di and
drug rj. The higher the score, the more likely that the association exists. To identify the promising candidate indicates for a specific drug, we rank all candidates according to their scores in
descending order. The detail of the OMC2 algorithm is described in Algorithm 3.
Algorithm 3: OMC2 Algorithm
Input: The drug similarity matrix ARR 2 IRm�m , the disease similarity
matrix ADD 2 IRn�n , the disease–drug association matrix ADR 2 IRn�m , parameters K, α, and β.
Outout: Predicted association matrix A�DR .
1. ADR1
KNN preprocessingðADR ; ADD ; KÞ;
"
#
ARR
;
2. M1 ¼
ADR1
3. ADR2
KNN preprocessingðADR ; ARR ; KÞ;
4. M2 ¼ ½ ADR2 ADD �;
" � #
ARR
BNNRðM1 ; a; bÞ;
5.
A�DR1
BNNRðM2 ; a; bÞ;
6. ½ A�DR2 A�DD �
A�

þA�

7. A�DR ¼ DR1 2 DR2 ;
8. return A�DR .
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OMC algorithm for tri-layer networks
OMC can be easily extended from bilayer networks (OMC2) to tri-layer networks (OMC3)
algorithm, where the disease–protein and drug–protein association information are incorporated to further improve prediction accuracy. Firstly, we collect drug–protein (target) interactions and disease–protein associations from different databases. This step has been discussed
in the previous section. Secondly, based on the two bilayer networks, i.e., the DrNet-Dis network and the DisNet-Dr network, we design two corresponding tri-layer networks. We integrate protein nodes and drug–protein associations into the DrNet-Dis network and construct
a drug–protein–disease network called DrNet-Pro-Dis, as showed in Fig 2(e). The block adjacency matrix of this tri-layer network is defined as
2
3
ARR
6
7
6
7
M1 ¼ 6 APR 7:
4
5
ADR1
Similarly, we integrate protein nodes and disease–protein associations into the DisNet-Dr network and create another tri-layer network called DisNet-Pro-Dr, as illustrated in Fig 2(f). The
block adjacency matrix of DisNet-Pro-Dr network is defined as
M2 ¼ ½ ADR2

ADP

ADD �:

Thirdly, the BNNR algorithm is carried out to fill out the missing entries of M1 and M2 to
obtain two predicted drug–disease association matrices. Finally, we calculate the average of
these two matrices as the final output. The detail of OMC3 the algorithm is described in Algorithm 4.
Algorithm 4: OMC3 Algorithm
Input: Drug similarity matrix ARR 2 IRm�m , disease similarity matrix
ADD 2 IRn�n , protein–drug association matrix APR 2 IRs�m , disease–protein
association matrix ADP 2 IRn�t , disease–drug association matrix ADR 2 IRn�m ,
parameters K, α, and β.
Output: Predicted association matrix A�DR .
KNN preprocessingðADR ; ADD ; KÞ;
1. ADR1
2
3
ARR
6
7
2. M1 ¼ 4 APR 5;
ADR1
3. ADR2
KNN preprocessingðADR ; ARR ; KÞ;
4. M2 ¼ ½ ADR2 ADP ADD �;
2 � 3
ARR
6 � 7
7
BNNRðM1 ; a; bÞ;
5. 6
4 APR 5
A�DR1
BNNRðM2 ; a; bÞ;
6. ½ A�DR2 A�DP A�DD �
A�

þA�

7. A�DR ¼ DR1 2 DR2 ;
8. return A�DR .

Results
In this section, we systematically evaluate the performance of our proposed methods (OMC2
and OMC3) for predicting drug-associated indications. First of all, several evaluation metrics
are introduced and parameter settings are discussed. In order to compare our methods with
several state-of-the-art approaches, we perform 10-fold cross-validation and de novo tests in
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Fig 2. The workflow of constructing the DrNet-Pro-Dis network and the DisNet-Pro-Dr network. (a) DrNet-Dis network and its similarity matrix. (b) Drug–
protein interactions and corresponding adjacency matrix. (c) Disease–protein associations and corresponding adjacency matrix. (d) DisNet-Dr network and its block
adjacency matrix. (e) DrNet-Pro-Dis network and its block adjacency matrix. (f) DisNet-Pro-Dr network and its block adjacency matrix.
https://doi.org/10.1371/journal.pcbi.1007541.g002

the gold standard dataset. Case studies are conducted to confirm the reliability of OMC3 in
practical applications. Then, the performance of OMC and comparison on bilayer and trilayer networks are discussed. Finally, we perform the same experiments on two other datasets
to further illustrate the effectiveness and robustness of OMC2 and OMC3.

Evaluation metrics
To evaluate the performance of our approaches, a 10-fold cross-validation experiment is
conducted to identify candidate diseases for specific drugs. In the gold standard dataset, all
approved drug–disease associations are randomly divided into ten parts with approximately
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equal sizes. Each part is treated as the testing set in turn, and the training set is comprised of
the remaining nine parts. To obtain convincing results, the 10-fold cross-validation is repeated
10 times and the final result is showed by the average value of the 10 folds. After the performing prediction, all candidate diseases associating with the test drug are ranked by their predicted scores in descending order. For a given rank threshold, the candidate disease is
considered as a True Positive (TP) if its rank is above the threshold; otherwise, it is treated as a
False Negative (FN). On the other hand, if the rank of a candidate disease had no association
with the test drug is greater than the threshold, it is considered as a False Positive (FP), otherwise, it is treated as a True Negative (TN). Based on varying ranking thresholds, we can calculate True Positive Rate (TPR) and False Positive Rate (FPR) by
TPR ¼

# of TPs
;
# of TPs þ # of FNs

FPR ¼

# of FPs
;
# of FPs þ # of TNs

and draw a Receiver Operating Characteristic (ROC) curve. Meanwhile, the area under the
ROC curve (AUC) is utilized to evaluate the overall performance of a method. Precision and
recall (equivalent to TPR) could be obtained to plot the precision-recall (PR) curve [25]. Due
to the fact that the top-ranked result is a more important measurement in real-life drug-repositioning applications, the number of the retrieved correct associations is reported under different top ranking values.

Parameter settings
In OMC2 and OMC3 algorithms, there are three hyper parameters to be determined, including α, β, and K. In this subsection, using the OMC2 algorithm as an example, we explain the
procedure of determining these parameters. The similar parameter determination procedure
can be extended to the OMC3 algorithm.
For α and β, we perform a 10-fold cross-validation to find the most appropriate values by
the grid search, which are chosen from {0.1, 1, 10, 100}. When the neighborhood size K is fixed
to 1, S1 Table shows the AUC values of OMC2 under different values of α and β on the gold
standard dataset. Our results show that the best performance is achieved by α = 1 and β = 10.
For K, we firstly assign 1 and 10 to α and β, respectively and then use cross validation to
pick an appropriate K value from {1, 5, 10, 15, 20, 25, 30}. S1 Fig shows the AUC values of
OMC2 under this setting. When K is 10, the best AUC value is achieved. Since the values of K
have little effect on AUC values, we can treat K = 10 as a prior knowledge in other datasets for
simplicity. Actually, We fixed the neighborhood size K to 10, the optimal values of α and β are
also equal to 1 and 10, respectively. The results are shown in S2 Table and it could further illustrate the stability of the parameter values.
Based on the above analysis, we finally choose α = 1, β = 10, and K = 10 for the gold standard dataset as the default parameters.

Comparison with other methods
In order to obtain convincing and fair comparison results, OMC2 and OMC3 are compared
with the five state-of-the-art approaches: BNNR [14], DRRS [12], MBiRW [6], DrugNet [5],
and HGBI [3]. The parameters in the compared approaches are set to either the default values
in their papers or the best value by the grid search, if the default values are not provided. We
rank the predicted indications and plot the ROC curves and PR curves to analyze the 10-fold
cross-validation results.
As shown in Fig 3, OMC2 and OMC3 outperform the other methods in ROC curves, PR
curves, and top-ranked results. More specifically, OMC2 and OMC3 obtain AUC values of
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Fig 3. The performance of all methods for predicting drug–disease associations in the 10-fold cross-validation. (a) ROC curves of prediction results. (b) PR
curves of predicting candidate diseases for drugs. (c) The number of correctly retrieved drug–disease associations for various rank thresholds.
https://doi.org/10.1371/journal.pcbi.1007541.g003

0.939 and 0.945, while BNNR, DRRS, MBiRW, DrugNet, and HGBI yield AUC values of
0.932, 0.930, 0.917, 0.868, and 0.829, respectively. In real-life drug-repositioning applications,
researchers particularly care about precision, because the precise prediction can significantly
reduce experimental cost and time. The PR curves show OMC2 and OMC3 achieve the second
best and the best precisions of 0.449 and 0.461, while BNNR, DRRS, MBiRW, DrugNet, and
HGBI have the precisions of 0.440, 0.375, 0.304, 0.192, and 0.130, respectively. It is important
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to note that OMC3 can successfully prioritize 46.1% true drug–disease associations at top
rank. A true drug–disease association is treated as the retrieved correct association when its
predicted rank is higher than the specified ranking threshold. The numbers of correct associations predicted by all methods under different top ranking values are shown in Fig 3(c). The
numbers of retrieved associations of both OMC2 and OMC3 exceed those of the other competing approaches. Specifically, among 1, 933 true drug–disease associations, 1, 493(77.2%)
and 1, 529(79.1%) associations are correctly predicted at top 10 by OMC2 and OMC3, while in
comparison, 1, 475(76.3%), 1, 413(73.1%), 1, 232(63.7%), 900(46.6%), and 752(38.9%) associations are identified by BNNR, DRRS, MBiRW, DrugNet, and HGBI, respectively.

Prediction of potential indications for new drugs
To evaluate the performance of OMC2 and OMC3 for identifying indications of novel drugs,
we conduct a de novo test, where these drugs with only one known drug–disease association
are chosen. For each of these drugs, the unique disease association is removed in turn as the
test sample, and other known drug–disease associations are used as the training samples.
There are totally 171 drugs with only one known associated disease in gold standard dataset.
As shown in Fig 4, OMC2 and OMC3 achieve the AUC values of 0.851 and 0.871, while
BNNR, DRRS, MBiRW, DrugNet, and HGBI have inferior results with the AUC values of
0.830, 0.824, 0.818, 0.782, and 0.746, respectively. OMC3 has demonstrated its advantages
measured by PR curves. For top-ranked results, OMC3 outperforms all methods at all ranking
thresholds. Meanwhile, OMC2 surpasses the compared approaches at top 5, 10, 30, 50 and
100, except for being inferior to DRRS at top 1. Specifically, 74 and 88 drugs are identified correctly at top 5 by OMC2 and OMC3, respectively. In comparison, 73, 62, 71, 52, and 36 drugs
are predicted by BNNR, DRRS, MBiRW, DrugNet, and HGBI, respectively. Summarizing
the above results, one can find that our OMC methods are effective to address the cold-start
problem to identify potential indications for novel drugs. In particular, OMC3 yields further
improvement over OMC2, indicating the effectiveness of incorporating target association
information in the tri-layer network.

Case studies
We apply OMC3 to predict new uses for already approved drugs in real applications. To predict novel indications for existing drugs in the gold standard dataset, we consider all known
associations between drugs and diseases as the training samples and the unknown drug–disease pairs as the candidate samples. By carrying out the OMC3 algorithm, the predicted scores
of all candidate pairs are obtained and sorted for each specific drug.
In order to verify the predicted diseases, we choose three representative drugs: Doxorubicin, Flecainide, and Levodopafour. We confirm the potential diseases associated with the given
drug by retrieving authoritative public databases, such as CTD [21], DrugBank, and KEGG
[26]. The newly predicted indications and their supporting evidences are listed in Table 1. One
can find that more than three novel indications are validated on top-5 for each representative
drug. As shown in this case study, OMC3 can be used as an effective method for identifying
new indications for specific drugs in practical applications. In order to provide more helpful
references for medical researchers, the top-30 candidate indications of each drug are listed in
S3 Table.

Effectiveness of OMC on performance
In order to evaluate the effectiveness of OMC, we compare OMC2 with algorithms using
only drug- or disease-side information in 10-fold cross-validation. The first algorithm, called
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Fig 4. Performance of all methods in predicting potential diseases for new drugs. (a) ROC curves of prediction results. (b) PR curves of predicting candidate
diseases for drugs. (c) Number of correctly retrieved drug–disease associations for various rank thresholds.
https://doi.org/10.1371/journal.pcbi.1007541.g004

OMC-drug, is to obtain ADR1 by BNNR in DrNet-Dis network, while the other one, called
OMC-disease, is to recover ADR2 by BNNR in DisNet-Dr network. As shown in S2 Fig, both
OMC-drug and OMC-disease are inferior to OMC2 in each fold in terms of AUC. In conclusion, consolidating drug- and disease-side associations in OMC2 is a better way to predict
drug–disease associations than just using one-side information.
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Table 1. The top-5 candidate diseases for Doxorubicin, Flecainide, and Levodopa.
Drugs
(DrugBank IDs)
Doxorubicin
(DB00997)

Flecainide
(DB01195)

Top-5 candidate diseases
(OMIM IDs)

Evidences

Dohle bodies (223350)
Reticulum cell sarcoma (267730)

CTD

Small cell cancer of the lung (182280)

CTD

Leukemia (109543)

CTD/DB/KEGG

Testicular germ cell tumor (273300)

CTD

Atrial fibrillation (608583)

CTD

Cardiac arrhythmia (115000)

CTD/DB

Diastolic hypertension (608622)

CTD

Hyperplastic myelinopathy (147530)
Nephropathy-hypertension (161900)
Levodopa
(DB01235)

Parkinson disease (168600)

CTD/DB/KEGG

Dementia (125320)

CTD/DB

Schizophrenia (181500)

CTD

Optic atrophy, hearing loss, and peripheral neuropathy (165199)

CTD

Hyperplastic myelinopathy (147530)
https://doi.org/10.1371/journal.pcbi.1007541.t001

Comparison on tri-layer networks
In this subsection, we illustrate the performance and the computational efficiency of different
approaches in tri-layer networks. BNNR, DRRS, DrugNet, and HGBI algorithms are taken
into account for extending from bilayer networks into tri-layer networks, in comparison with
OMC3. Since the protein association information is incorporated, the resulted affinity matrix
of the tri-layer network is significantly enlarged. This also poses computational challenges in
the factorization algorithms in matrix completion, which often grow cubically. The running
time of each approach is obtained on a Linux server with CPU 2.30 GHz and 128 GB memory.
As described in our previous works, BNNR and DRRS constructed the same bilayer networks between drugs and diseases. In order to construct a tri-layer heterogeneous network, we
integrate protein-related information into the network, including protein–protein similarities,
drug–protein interactions, and disease–protein associations. Accordingly, we get the corresponding square, symmetric adjacency matrix defined as follows,
2

ARR

ATDR

ATPR

3

6
6
M ¼ 6 ADR
4

ADD

7
7
ATPD 7;
5

APR

APD

APP

where APP represents the protein–protein similarity matrix, which is calculated based on the
amino acid sequence alignment by Rcpi [27]. The programs for completing the matrix M by
BNNR and DRRS are called BNNR3 and DRRS3, respectively. For DrugNet, it is also applied
to tri-layer networks by integrating target-related information [5], which is denoted as
DrugNet3 here. DrugNet3 can predict drug–disease relationships by propagating information
in the drug–target–disease network. Based on the guilt-by-association principle, the authors of
HGBI had extended bilayer networks into tri-layer networks by integrating drug, target, and
disease information [4], which was called TL-HGBI (denotes HGBI3 here).
The 10-fold cross-validation is uniformly conducted in the same gold standard dataset
for OMC3, BNNR3, DRRS3, DrugNet3, and HGBI3. As shown in Fig 5(a) and 5(b), OMC3
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Fig 5. Method comparison in bilayer networks and tri-layer networks. (a) ROC curves of prediction results. (b) PR curves of prediction results. (c) The average
running time of each fold in the 10-fold cross-validation.
https://doi.org/10.1371/journal.pcbi.1007541.g005

outperforms the other approaches measured by the AUC values of the ROC curves and the
precision. Specifically, OMC3 obtains the best AUC value of 0.945, while BNNR3, DRRS3,
DrugNet3, and HGBI3 have the AUC values of 0.932, 0.932, 0.835, and 0.855, respectively.
The PR curves show that OMC3 obtains the best precision with 0.460, while BNNR3,
DRRS3, DrugNet3, and HGBI3 have the precision values of 0.431, 0.329, 0.093, and 0.227,
respectively.
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Surprisingly, a method extended from bilayer networks into tri-layer networks does not
necessary improve the prediction performance. In fact, only OMC and HGBI obtain performance improvement in tri-layer networks over bilayer ones. BNNR3, DRRS3, and DrugNet3
yield even worse performance when tri-layer networks are used compared to the corespondent
algorithms on bilayer networks. This is due to the fact that protein–protein similarities calculated by the algorithm contain a large amount of “noise”, which causes BNNR3, DRRS3, and
DrugNet3 to degrade their prediction performance. In contrast, OMC3 avoids the use of protein–protein similarities and the information OMC3 used is experimentally proven, such as
drug–protein interactions and disease–protein associations, which in turn leads to performance improvement over OMC2 on bilayer networks.
As shown in Fig 5(c), the average running time of BNNR and DRRS increase sharply from
bilayer networks (BNNR2 and DRRS2) to tri-layer networks (BNNR3 and DRRS3), due to the
increase of the affinity matrix. Nevertheless, this does not have such a significant impact on
OMC, DrugNet, and HGBI. For OMC, this is because OMC keeps the matrix completion computation at the bilayer network level. As a result, OMC is not only better in terms of the prediction performance, but is also computational efficiency.

Experiments on the other datasets
We apply OMC2 and OMC3 to two other datasets, including Cdataset [6] and DNdataset [5],
to demonstrate their robustness. Cdataset contains 663 drugs collected in DrugBank, 409 diseases obtained in OMIM database, and 2, 352 known drug–disease associations. In addition,
we have collected drug–protein interactions related to drugs of Cdataset from DrugBank and
retrieved a total of 3, 251 associations between 637 drugs and 891 proteins. For disease–protein
associations, we download disease–gene interactions related to diseases of Cdataset from CTD
database, and map genes into proteins in the UniprotKB database. There are 1, 280 associations between 226 diseases and 1, 002 proteins. The drug similarity and disease similarity are
calculated in the same way as described in the previous section. DNdataset includes 1, 490
drugs registered in DrugBank, 4, 516 diseases annotated by Disease Ontology (DO) terms, 18,
107 proteins extracted from BioGRID, 11, 658 disease–protein associations directly extracted
from the disease and gene annotations (DGA), 4, 026 drug–protein interactions collected in
DrugBank, and 1, 008 known drug–disease associations. We evaluate the performance of our
methods on Cdataset and DNdataset by performing a 10-fold cross-validation and de novo
experiments.
For Cdataset, as shown in S3(a)–S3(c) Fig, OMC2 and OMC3 demonstrate superior performance in terms of ROC curve, PR curve, and top-ranked results in the 10-fold cross-validation. Specifically, OMC2 and OMC3 obtain the AUC values of 0.953 and 0.957 in the ROC
curves, while BNNR, DRRS, MBiRW, DrugNet, and HGBI have 0.948, 0.947, 0.933, 0.903, and
0.858, respectively. The PR curves indicate that OMC2 and OMC3 achieve the second best precision of 0.476 and the best precision of 0.489, while the precision values in BNNR, DRRS,
MBiRW, DrugNet, and HGBI are 0.471, 0.403, 0.351, 0.239, and 0.168, respectively. In addition, OMC2 and OMC3 outperform the other methods in the top-ranked results with respect
to different ranking thresholds. In the de novo test, there are 177 drugs with only one known
associated disease in Cdataset. As shown in S4(a)–S4(c) Fig, OMC2 and OMC3 obtain the
AUC values of 0.830 and 0.846, respectively, while BNNR, DRRS, MBiRW, DrugNet, and
HGBI have the AUC values of 0.812, 0.819, 0.804, 0.785, and 0.732, respectively. Both OMC2
and OMC3 exceed the other methods in terms of AUC values as well. For top-ranked results,
among 177 test drugs, 100 (56.5%) drugs are correctly identified at top 10 by OMC3, while
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only 87 (49.2%), 78 (44.1%), 80 (45.2%), 61 (34.5%), and 48 (27.1%) drugs are predicted by
BNNR, DRRS, MBiRW, DrugNet, and HGBI, respectively.
For DNdataset, in the 10-fold cross-validation results shown in S5(a)–S5(c) Fig, OMC2 and
OMC3 obtain the AUC values of 0.957 and 0.965, while BNNR, DRRS, MBiRW, DrugNet, and
HGBI yield the AUC values of 0.955, 0.934, 0.956, 0.950, and 0.921, respectively. Similar to
that of Cdataset, OMC2 obtains the second best precision of 0.360 and OMC3 obtains the best
precision of 0.369 in PR curves. Moreover, OMC2 and OMC3 outperform the other methods
on top-ranked results at different ranking thresholds. In the de novo test, OMC3 also outperforms the other methods. As shown in S6(a)–S6(c) Fig, OMC2 and OMC3 obtain the AUC
values of 0.963 and 0.972, while BNNR, DRRS, MBiRW, DrugNet, and HGBI have the AUC
values of 0.956, 0.946, 0.970, 0.969, and 0.928, respectively. For top-ranked results, among 347
test drugs, 228 (65.7%) and 231 (66.6%) drugs are correctly identified at top 1 by OMC2 and
OMC3, while only 218 (62.8%), 213 (61.4%), 219 (63.1%), 156 (45.0%), and 150 (43.2%) drugs
are predicted by BNNR, DRRS, MBiRW, DrugNet, and HGBI, respectively. In summary, the
above results on Cdataset and DNdataset demonstrate the robustness and generalization of
OMC.

Discussion
In this study, we have proposed a novel OMC method for predicting drug-associated indications, which can effectively integrate multiple types of drug and disease information. In addition, our method can be simply extended from bilayer networks to tri-layer networks by
incorporating drug-target associations. Furthermore, OMC effectively avoids the use of noisy
data in tri-layer networks. The performance of our methods (OMC2 and OMC3) are validated
by the cross validation, de novo experiments, and case studies. The experimental results indicate that our methods are effective compared with the latest approaches, particularly for de
novo drugs.
However, OMC has two potential limitations. First, the drug and disease similarity computations in this work may be not optimal. More reliable similarity measures, for example consensus integrating multiple similarities computations from different aspects could improve the
performance of OMC. Second, OMC must perform matrix completion twice from both drugside and disease-side before the final predicted score is obtained.
OMC can actually be used on other drug-related predictions, such as synergistic drug combination and small molecule–miRNA association prediction. The synergistic drug combination is based on the assumption that principal drugs which obtain the synergistic effect with
similar adjuvant drugs are often similar and vice versa [28]. That means the drug combination
matrix is also of low-rank. Therefore, OMC can be applied to predict potential synergistic
drug combinations by integrating the drug similarity matrix and the drug–target interaction
matrix. In addition, it may avoid classifying principal drugs and adjunct drugs before obtaining the final score of drug combinations. MiRNAs play an important role in the initiation and
development of various human diseases. Several drug-like compound libraries targeting different miRNAs have been successfully screened in cell assays, further demonstrating the possibility of targeting miRNAs with small molecules. Hence, it is very meaningful and promising to
develop computational models for drug repositioning based on drug related miRNA. Some
original and novel methods have been proposed in recent years [29]. Especially, based on trilayer heterogeneous networks, more prior information is used to obtain better prediction performance [30]. In the future, we plan to extend our OMC method to explore drug combinations and miRNA-small molecule associations for drug repositioning.
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Supporting information
S1 Fig. The AUC values are indicated by the OMC2 algorithm when the neighborhood size
K is chosen from {1, 5, 10, 15, 20, 25, 30} in the cross validation.
(TIF)
S2 Fig. Performance comparison of the OMC2, OMC-drug and OMC-disease in the
10-fold cross-validation in terms of AUC. The result of each fold is presented.
(TIF)
S3 Fig. (a) ROC curves of prediction results. (b) PR curves of predicting candidate diseases
for drugs. (c) The number of correctly retrieved drug–disease associations for various rank
thresholds. The performance of all methods for predicting drug–disease associations in the
10-fold cross-validation on CDataset.
(TIF)
S4 Fig. (a) ROC curves of prediction results. (b) PR curves of predicting candidate diseases
for drugs. (c) The number of correctly retrieved drug–disease associations for various rank
threshold. The performance of all methods in predicting potential diseases for new drugs on
CDataset.
(TIF)
S5 Fig. (a) ROC curves of prediction results. (b) PR curves of predicting candidate diseases
for drugs. (c) The number of correctly retrieved drug–disease associations for various rank
thresholds. The performance of all methods for predicting drug–disease associations in the
10-fold cross-validation on DNdataset.
(TIF)
S6 Fig. (a) ROC curves of prediction results. (b) PR curves of predicting candidate diseases
for drugs. (c) The number of correctly retrieved drug–disease associations for various rank
threshold. The performance of all methods in predicting potential diseases for new drugs on
DNdataset.
(TIF)
S1 Table. The AUC values under different values of α and β in the 10-fold cross-validation
for the gold standard dataset.
(DOC)
S2 Table. The AUC values based on K = 10 for α and β in the 10-fold cross-validation for
the gold standard dataset.
(DOC)
S3 Table. The top-30 candidate indications of all drugs listed by OMC3.
(XLSX)
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